Clinical trialRecruiting clinical trial

New Clinical Trial for SCN1A-Related Genetic Epilepsy

A new phase 2 clinical trial is testing a targeted medication for children with Dravet Syndrome and other SCN1A-related conditions.

Educational summary - not medical advice. Always consult your child's care team.
EpilepsyClinical Trials·

Research Profile

Source:ClinicalTrials.gov

Published: June 2, 2026

Added to SpecialCircle: June 8, 2026

Evidence Level

Clinical trial

Research Status

Recruiting clinical trial

Key takeaways

  • •The trial is testing a drug designed to target the specific genetic cause of the seizures.
  • •Participants must have a confirmed SCN1A genetic mutation.
  • •The study is looking for children and adolescents within a specific age range.
  • •The primary goal is to see if the drug is safe and if it reduces seizure counts.

Source

ClinicalTrials.gov · Clinical trial registry

Read the original source

Plain-language summary

A new clinical trial has opened to test a medicine for children who have a mutation in the SCN1A gene, which often causes a severe form of epilepsy called Dravet Syndrome. Unlike many standard medications that treat symptoms, this experimental drug tries to help the gene function more normally.

The trial is currently looking for volunteers to help determine the right dosage and ensure the treatment does not cause harmful side effects.

How it works

Science explained

Unlike many standard medications that treat symptoms, this experimental drug tries to help the gene function more normally. It is designed to target the specific genetic cause of the seizures, addressing the underlying condition rather than just managing symptoms.

Why parents may care

For families with a genetic diagnosis, this represents research specifically tailored to their child's underlying condition rather than a general epilepsy treatment.

Clinical trial journey

  1. Phase

    Phase 2 clinical trial, focused on determining dosage and assessing safety.

  2. Enrollment

    Recruiting

  3. Data collection

    Data is being collected to evaluate the drug's safety and its impact on reducing seizure counts.

Who may be eligible

Participants must have a confirmed SCN1A genetic mutation and be children or adolescents within a specific age range.

What is still unknown

It is not yet known if this drug is safe for long-term use in children or if it will be more effective than the medications currently available on the market.

Frequently asked questions about Epilepsy

This clinical trial is evaluating a new medication for children with SCN1A-related genetic epilepsy, including Dravet Syndrome. Its primary goal is to determine a safe dosage and assess if the treatment can reduce seizure counts, targeting the genetic cause of the condition.

Terminology glossary

SCN1A gene
A specific gene whose mutation is often linked to severe forms of epilepsy, such as Dravet Syndrome.
Dravet Syndrome
A severe and rare form of epilepsy that frequently results from a mutation in the SCN1A gene.
Clinical trial
A research study involving human participants to test the safety and effectiveness of new medical treatments or interventions.
Genetic mutation
A permanent change in the DNA sequence of a gene, which can sometimes lead to health conditions like epilepsy.
Epilepsy
A neurological disorder characterized by recurrent, unprovoked seizures due to abnormal brain activity.

Questions to ask your doctor or therapist

  • ?Is my child's specific genetic mutation a match for this type of clinical trial?
  • ?What are the potential risks and benefits of participating in a phase 2 trial?
  • ?How would participating in a trial change our current treatment plan?

⚕️ This research digest is for educational and community support purposes only. It is not medical advice, diagnosis, or treatment. Always speak with a qualified doctor, therapist, or medical professional before making decisions about care.

Related research

Update on the NGN-401 Gene Therapy Study

Researchers have finished giving the study treatment to all 25 children in a major trial for a new gene therapy called NGN-401.

Study Investigates Immune System 'Gatekeepers' for Gene Therapy

A new clinical study is checking how many children have antibodies that might block gene therapy from working.

Recent Breakthroughs in Down Syndrome Research: Key Takeaways from the 2026 Global Conference

Scientists recently gathered to share new findings on brain health, memory, and aging in individuals with Down Syndrome.

FDA Discusses Paths to Earlier Gene Therapy for Children

The FDA recently hosted a workshop to find ways to get gene therapy into pediatric clinical trials sooner and more safely.

Talk to parents who truly understand

SpecialCircle is a free, private community. Ask questions, share what works, and never feel alone.

Find parents who understand Ask the community